PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Vivian G. Oehler, MD - The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care
The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what’s next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don’t miss the ‘sequel’ to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies